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We read with interest the recent paper by Lee et al.1
published in TVST entitled “The Implications of an
Ab Interno Versus Ab Externo Surgical Approach
on Outflow Resistance of a Subconjunctival Drainage
Device for Intraocular Pressure Control.”
We would like to present a few important considerations that may help readers better understand
patient outcome predictors for ab interno and ab
externo procedures. Wound healing in a clinical setting
compared to microfluidics in a non-healing rabbit eye
is clearly very different.
First, the title of the manuscript creates confusion
because recent trends in surgery for subconjunctival
drainage devices include ab interno (through a clear
corneal incision that then tracks through sclera) or
ab externo (from the sclera to the anterior chamber).
This study does not look at the difference in how
devices are placed but rather the difference in surgically
dissecting conjunctiva versus no surgical dissection in
an ex vivo model without blood supply or inflammatory mediators. The complete absence of wound
healing and conjunctival closure and the fact that the
proximal portion of the microstent does not rest in
the anterior chamber as in the surgical eye severely
limit this study from being clinically applicable. The
resistance to outflow can be significantly manipulated
or altered by these techniques, as well as by the use
of perioperative antifibrotic agents. In addition, the
authors state that the flow resistance of the standalone Xen45 gel stent is 10.3 mm Hg at a flow rate
of 2 μL/min. The actual resistance for the Xen45 gel
stent at 2 μL/min has been measured at 6.28 mm Hg
and calculated via the Hagen–Poiseuille equation to be
6.05 mm Hg at 37°C.2
This article seems to inappropriately position the
Xen gel stent and the InnFocus/PreserFlo microshunt

against one another based purely on surgical technique,
which is likely neither appropriate nor accurate,
especially because the Xen gel stent can and is being
placed ab externo with an open conjunctival technique.
To our knowledge, there are no peer-reviewed studies
directly comparing the Xen45 gel stent and the InnFocus microshunt.
The discussion section contains several statements
that are concerning, likely emanating from the difference between a microfluidics ex vivo rabbit model and
what is seen in a clinical research setting with variable
wound healing:
1. The authors compared various peer-reviewed
articles on the Xen45 gel stent and the InnFocus microshunt; however, these quoted studies
are vastly different in terms of methods, patient
population, and follow up, as well as dose of
mitomycin C (MMC). The authors also did not
cite the US Food and Drug Administration pivotal
trial on the Xen gel stent nor did they cite the
international comparative study of the Xen gel
stent versus trabeculectomy.3,4 The conclusion
made by the authors is that one implant is perhaps
superior at lowering intraocular pressure than
another implant. Although this may eventually
turn out to be true, there are no studies supporting
this statement, and the current experiment was not
designed to test that hypothesis.
2. The authors refer to the Moorfields Safer Surgery
System to make statements about the Xen gel stent
and InnFocus microshunt. Although this system
remains a tremendous innovation for improving
safety for trabeculectomy, there is no study confirming that the system is applicable to subconjunctival
filtration with microshunt devices. Moreover, there
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is no study indicating that this system is applicable
when one injects MMC in the far posterior fornix
during subconjunctival filtration procedures.
The authors also make a statement that performing a conjunctival dissection allows for greater
predictability of directing aqueous flow posteriorly;
however, their paper does not directly support this
observation.
The authors postulate on a valve-like mechanism
of the conjunctiva but make no comment regarding
the position of the stent with reference to Tenon’s
capsule, which clearly has a major impact on all
types of filtration surgery, including microshunt
surgery. This theory is likely difficult to test or evaluate in their ex vivo model when tissues are not alive,
vascularized, or even closed.
The authors make a statement that MMC injections
are inherently more random and less predictable.
Granted there is less long-term information regarding MMC injections and bleb morphology, but
there is plenty of evidence to demonstrate improved
bleb morphology and trabeculectomy success rates
with MMC injection versus sponge use.5
The authors make a statement that there is
“unpredictability of the bleb development with
devices implanted via the ab interno approach
with preimplantation subconjunctival injection of
MMC.” With the recent advances in subconjunctival minimally invasive glaucoma surgical (MIGS)
surgery, including proper microstent placement
and MMC application, we have seen significantly
improved predictability, contrary to the authors’
laboratory work.

Although this is a well-designed study to evaluate the outflow resistance of a specific subconjunctival drainage device in an ex vivo model, we are
concerned that some of the authors’ conclusions are
not supported by this manuscript. Subconjunctival
MIGS surgeons, especially nascent ones, must be
vigilant in incorporating both laboratory and clinical
findings in order to develop a meaningful perspective
of subconjunctival filtration when approaching both ab
interno and ab externo surgery.
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